By Alexander Cohen
WASHINGTON, June 2, 2004 — In February of this
year, the latest breakthrough in the field of stem cell research was
announced in South Korea by scientists who had successfully cloned
human embryos and produced a viable stem cell line from them. Hailed
with both interest and alarm, this advance increased interest in the
rapidly-growing Asian biotechnology sector and heightened the fears
of scientists and ethicists worldwide that developments in stem cell
research would be applied to the pursuit of human cloning
technology.
The privately-funded experiment, which took
place at Seoul National University under the guidance of Korean
Hwang Woo-suk and American Jose Cibelli, was only the latest in a
group of announcements from research institutions in Asia in the
last few years, and demonstrates that cloning research is becoming
"globalized" like any other commodity.
There are many indigenous efforts underway
around Asia to advance genetic technologies. Chinese scientists at
various research institutions have reported successful experiments
in human cloning, including the production of human-rabbit hybrid
embryonic stem cells, according to the claims of Professor Lu
Guangxiu at Xiangya Medical College, who told the Wall Street
Journal in March of 2002 that researchers at the College had
been successfully cloning embryos for two years. China has
reportedly been increasing its funding for cloning and other
biotechnology research efforts. From 1995 to 2000, it reportedly
spent over $180 million and after 2000 has reportedly boosted
funding for the next five years to over $600 million. In Japan,
scientists at Kyoto University announced in January that they had
successfully produced embryonic stem cells domestically for the
first time.
Although stem cell research efforts have been
in place for several years, the top countries in Asia have only
recently begun to regulate the science. Among the largest Asian
countries, Japan was an early pioneer in regulating human embryo
research, pledging international cooperation on the issue following
pronouncements on the subject at a June 1997 meeting of the Group of
Eight in Denver, Colorado. Japan subsequently enacted legislation in
late 2000 criminalizing the cloning of human embryos for
reproductive purposes. China enacted regulations early this year to
allow the cloning of human embryos for research, and South Korea
enacted similar legislation to allow research days ahead of the
February announcement.
Meanwhile, regulation in the United States is
still at an impasse. The United States currently has no
comprehensive law, and legislation that would have banned both
research and reproductive cloning has failed to reach a vote in the
Senate after approval in the House of Representatives in July 2001.
A growing number of U.S. legislators seem
prepared to support research on therapeutic cloning. Responding to
the current administration's policy, which strongly limits research
done with federal funds, over 200 members of the House sent a letter
to President Bush late last month that called on the administration
to ease current restrictions amid fears that other countries,
especially in Asia, are overtaking the U.S. in what is seen as a
vitally important area of research. Several western scientists have
been conducting their research in Asian countries in the past few
years, including Cibelli, formerly of Advanced Cell Technology, an
early U.S. pioneer of embryo research, as well as Alan Colman, now
located in Singapore, one of the scientists who helped create the
first mammalian clone, the sheep Dolly.
While an international framework to regulate
cloning remains stalled in the United Nations, some Asian countries
are offering more stable climates for researchers to pursue their
work. |